Universität zu Köln

Brunner, Thomas B., Blanck, Oliver ORCID: 0000-0003-1391-1308, Lewitzki, Victor, Abbasi-Senger, Nasrin, Momm, Felix, Riesterer, Oliver ORCID: 0000-0002-9508-0546, Duma, Marciana Nona, Wachter, Stefan, Baus, Wolfgang, Gerum, Sabine, Guckenberger, Matthias ORCID: 0000-0002-7146-9071 and Gkika, Eleni (2019). Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother. Oncol., 132. S. 42 - 48. CLARE: ELSEVIER IRELAND LTD. ISSN 1879-0887

Full text not available from this repository.

Abstract

Purpose: Non-resectable cholangiocarcinoma (CCC) is a significant therapeutic challenge because of bad prognosis. This study analyzed the outcome after SBRT for intra-and extrahepatic CCC. Material and methods: Sixty-four patients with 82 CCC lesions from a retrospective multicenter database were analyzed. Available parameters were analyzed for local control (LC), overall survival (OS) and toxicity. Results: Median follow-up time for patients alive was 35 months (range 7-91 months). Median overall survival (OS) time was 15 months; 2-year and 3-year OS rates were 32% and 21%. Median prescribed biological effective radiation dose (BED, alpha/beta = 10) was 67.2 Gy(10) (range, 36-115 Gy(10); SD: 20 Gy(10)) in median 8 fractions (range, 3-17; 95% CI: 3-12), median BEDmax was 91 Gy(10). BED was the only prognostic factor for LC and OS. Patients receiving BEDmax >91 Gy(10) had a median OS of 24 months vs. 13 months for those receiving lower doses (p = 0.008). LC rates at 12 and 24 months were 91% and 80% for BEDmax > 91 Gy(10) vs. 66% and 39% for lower doses (p = 0.009). Of note, tumor size and PTV were neither predictive nor prognostic for LC and OS. Treatment tolerance was good with 17% of grade 1 gastroduodenitis, 11% of grade 2-3 cholangitis and 4.7% of grade 3 gastrointestinal bleeding. Conclusion: This is the largest reported series on SBRT in cholangiocarcinoma. Overall survival and local control were significantly improved after higher doses (BED) and tolerance was excellent. (C) 2018 Elsevier B.V. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Brunner, Thomas B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Blanck, Oliver UNSPECIFIED orcid.org/0000-0003-1391-1308 UNSPECIFIED Lewitzki, Victor UNSPECIFIED UNSPECIFIED UNSPECIFIED Abbasi-Senger, Nasrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Momm, Felix UNSPECIFIED UNSPECIFIED UNSPECIFIED Riesterer, Oliver UNSPECIFIED orcid.org/0000-0002-9508-0546 UNSPECIFIED Duma, Marciana Nona UNSPECIFIED UNSPECIFIED UNSPECIFIED Wachter, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Baus, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Gerum, Sabine UNSPECIFIED UNSPECIFIED UNSPECIFIED Guckenberger, Matthias UNSPECIFIED orcid.org/0000-0002-7146-9071 UNSPECIFIED Gkika, Eleni UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-155620
DOI:	10.1016/j.radonc.2018.11.015
Journal or Publication Title:	Radiother. Oncol.
Volume:	132
Page Range:	S. 42 - 48
Date:	2019
Publisher:	ELSEVIER IRELAND LTD
Place of Publication:	CLARE
ISSN:	1879-0887
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RADIATION-THERAPY; LIVER-TUMORS Multiple languages Oncology; Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15562